<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794923</url>
  </required_header>
  <id_info>
    <org_study_id>B3491010</org_study_id>
    <nct_id>NCT01794923</nct_id>
  </id_info>
  <brief_title>Topical Ibuprofen for Delayed Onset Mulscle Soreness</brief_title>
  <official_title>Placebo-controlled, Double-blind Evaluation of the Efficacy and Safety of Ibuprofen 5% Topical Gel for the Treatment of Delayed-onset Muscle Soreness of the Elbow Flexor Muscles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy and safety of Ibuprofen 5% Topical Gel
      versus placebo administered two or three times daily for the treatment of pain associated
      with delayed onset muscle soreness following intense eccentric exercise of the elbow flexor
      muscles.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle Soreness with Movement (change from baseline) over 0-24 hours post Dose 1</measure>
    <time_frame>Pre-dose, hourly from Hours 1 through 12, and at Hour 24</time_frame>
    <description>time weighted Sum of Muscle Soreness with Movement (change from baseline) over 0-24 hours post Dose 1 (SMSM0-24)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the time weighted sum of muscle soreness with movement</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Change from baseline in the time weighted sum of muscle soreness with movement over 24-48 hours, 48-72 hours, and 0-72 hours, and the change from baseline in muscle soreness with movement at each assessment time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the time weighted sum of spontaneous muscle soreness</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Change from baseline in the time weighted sum of spontaneous muscle soreness over 0-24 hours, 24-48 hours, 48-72 hours, and 0-72 hours and the change from baseline in spontaneous muscle soreness at each assessment time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time weighted sum of muscle soreness relief</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Time weighted sum of muscle soreness relief over 0-24 hours, 24-48 hours, 48-72 hours, and 0-72 hours and the relief score at each assessment time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in muscle stiffness</measure>
    <time_frame>24 hours</time_frame>
    <description>Change from baseline in muscle stiffness at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Assessment of Medication</measure>
    <time_frame>72 hours</time_frame>
    <description>Subject Global Assessment of Medication at Hour 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of doses of rescue medication</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Number of doses of rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects taking rescue medication</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Percentage of subjects taking rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue medication following each dose</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Time to rescue medication following each dose</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ibuprofen 5% topical gel BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBU BID (Treatment A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo topical gel BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID (Treatment B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 5% topical gel TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBU TID (Treatment C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo topical gel TID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo TID (Treatment D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBU BID</intervention_name>
    <description>10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days</description>
    <arm_group_label>Ibuprofen 5% topical gel BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BID</intervention_name>
    <description>10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days</description>
    <arm_group_label>Placebo topical gel BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBU TID</intervention_name>
    <description>10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days</description>
    <arm_group_label>Ibuprofen 5% topical gel TID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo TID</intervention_name>
    <description>10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days</description>
    <arm_group_label>Placebo topical gel TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Males or females, 18 to 65 years of age, who have not engaged in upper extremity fitness
        activities for a minimum of 3 months prior to entry in the study; subjects must be willing
        to refrain from use of pharmacologic or non pharmacologic treatments (ie, heat, ice,
        massage) and other forms of soreness relief during the study

        Exclusion Criteria:

        Use of corticosteroids or short- or long-acting non-steroidal anti-inflammatory drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3491010&amp;StudyName=Topical%20Ibuprofen%20for%20Delayed%20Onset%20Mulscle%20Soreness</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>April 11, 2014</last_update_submitted>
  <last_update_submitted_qc>April 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Delayed onset muscle soreness</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>topical</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

